Author of the article: GlobeNewswire
Publishing date: Jul 19, 2021  â¢Â 4 hours ago  â¢Â 4 minute read  â¢Â
Article content
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) â Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.
(1)
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.
Immorna s unique mRNA construction and established versatile process platform are suitable for the development of self-replicating mRNA as well as conventional non-replicating mRNA products, enabling the construction of a customized form of mRNA molecule for a specific disease. In terms of deliver
Junshi Biosciences
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platfor
Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company s commercialization planning and operations. We are delighted to have Wei join Junshi s senior leadership team, said Mr. Jun Xiong, Chairman of Junshi Biosciences. Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world.
Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
July 01, 2021 21:09 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations.
“We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company t